DBV Technologies (DBVT) Stock Analysis

DBV Technologies (DBVT) is a publicly traded company in the HEALTHCARE sector. It trades at $18.23, carries a market capitalization of $1.11B. This page summarizes the public market data, fundamentals, and frequently asked questions for DBVT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $18.23
• Market Cap: $1.11B
• EPS: $-4.50
• 52-Week High: $26.18
• 52-Week Low: $7.94

Market Sentiment

DBV Technologies currently has a Neutral sentiment score of 0.10.

About DBV Technologies

DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, specializing in the development of novel epicutaneous immunotherapy products for the treatment of food allergies. Utilizing its proprietary Viaskin™ technology platform, DBV aims to provide non-invasive treatment solutions that facilitate allergen desensitization, significantly improving patient quality of life. The company’s robust pipeline, which includes lead candidates specifically...

GNG Research Analysis

GNG Research scores DBV Technologies (DBVT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DBVT.

Frequently Asked Questions

Does DBVT pay dividends?

DBV Technologies (DBVT) does not currently pay a regular dividend.

What is DBVT's market cap?

DBV Technologies (DBVT) has a market capitalization of $1.11B with a current stock price of $18.23.